Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Background CHF therapy remained unchanged.

What Was Measured

Topics PubMed links to this paper include Anaerobic Threshold, Cardiomyopathy, Dilated, Cardiovascular System, Chronic Disease, Echocardiography, Exercise Tolerance and Growth Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.